About the Company
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma's lead product candidate, OC-01 (varenicline) nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. In pre-clinical and clinical studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism of action via activation of the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
62
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $OYST News
Oyster Point's drug becomes first FDA-approved nasal spray to treat dry eyes
(Reuters) -Oyster Point Pharma Inc's treatment for dry eye disease became the first U.S. approved nasal spray for the chronic condition on Monday, sending the drug developer's shares about 19% ...
IPO Outlook For The Week: Chinese Media, Chinese Real Estate, Dry-Eye Therapy
Oyster Point Pharma, Inc. (NASDAQ: OYST) will issue 5 million shares between $16 and $18 Thursday on the Nasdaq. The offering represents 24.3% of outstanding shares and is expected to raise about ...
Viatris (VTRS) to Report Q2 Earnings: What's in the Offing?
Viatris Inc. Price, Consensus and EPS Surprise Viatris ... In January, Viatris completed the acquisitions of Oyster Point Pharma and Famy LifeSciences to establish a new division, Viatris Eye ...
Viatris (VTRS) to Report Q4 Earnings: Is a Beat in Store?
Viatris Inc. Price, Consensus and EPS Surprise Viatris ... VTRS completed the acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new division, Viatris Eye Care.
Peter W. Sonsini's Net Worth
Who is Peter W. Sonsini? Peter W. Sonsini has an estimated net worth of $898 Million. This is based on reported shares across multiple companies, which include Desktop Metal, Inc., Cascadian ...
Oncology Pharma Inc ONPH
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Nuvectis Pharma, Inc. (NVCT)
Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...
Anthony A.. Florence Jr's Net Worth
Who is Anthony A.. Florence Jr? Anthony A.. Florence Jr has an estimated net worth of $890 Million. This is based on reported shares across multiple companies, which include Arcellx, Inc ...
General Oyster Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Multi-vehicle crash on Oyster Point Rd. sends 2 to hospital
Newport News Police said the crash on Oyster Point Road at Canon Boulevard involved four vehicles. Officers responded to the scene just after 7 a.m. Newport News Police said the crash on Oyster ...
Evoke Pharma, Inc. (NASDAQ:EVOK): Are Analysts Optimistic?
We feel now is a pretty good time to analyse Evoke Pharma, Inc.'s (NASDAQ ... have to grow each year in order to reach the breakeven point by 2026? Working backwards from analyst estimates ...
Oncology Pharma Inc ONPH
We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ...
Loading the latest forecasts...